CEACAM6: A Novel Marker of Chronic Obstructive Pulmonary Disease Susceptibility?
- PMID: 37219336
- PMCID: PMC10273108
- DOI: 10.1164/rccm.202303-0610ED
CEACAM6: A Novel Marker of Chronic Obstructive Pulmonary Disease Susceptibility?
Comment on
-
CEACAM6 as a Novel Therapeutic Target to Boost HO-1-mediated Antioxidant Defense in COPD.Am J Respir Crit Care Med. 2023 Jun 15;207(12):1576-1590. doi: 10.1164/rccm.202208-1603OC. Am J Respir Crit Care Med. 2023. PMID: 37219322
References
-
- Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers . 2015;1:15076. - PubMed
-
- Mathers CD, Lopez AD, Murray CJL. In: Global burden of disease and risk factors. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. Washington, DC: The International Bank for Reconstruction and Development/The World Bank; 2006. The burden of disease and mortality by condition: data, methods, and results for 2001; pp. 45–234. - PubMed
-
- Benincasa G, DeMeo DL, Glass K, Silverman EK, Napoli C. Epigenetics and pulmonary diseases in the horizon of precision medicine: a review. Eur Respir J . 2021;57:2003406. - PubMed
-
- Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med . 2014;35:71–86. - PubMed
-
- Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J . 2019;54:1900651. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
